Related Experiment Video
Updated: Jun 20, 2026
10:28
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
[PET/CT in breast cancer: an update]
D Groheux1, J-L Moretti, S Giacchetti
1Service de médecine nucléaire, Pôle imagerie cancérologie PIC, hôpital Saint-Louis, Assistance publique des Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75475 Paris cedex 10, France. dgroheux@yahoo.fr
Bulletin Du Cancer
|September 18, 2009
Summary
18F-FDG PET/CT is valuable for managing high-risk breast cancer, detecting metastases, and assessing treatment response. It is not recommended for early-stage tumors or as a substitute for sentinel lymph node biopsy.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Background:
- 18F-FDG PET/CT plays a role in breast cancer management.
- New tracers like F-18 fluoro-L-thymidine, 18-fluoro-17-B-estradiol, and sodium fluoride are also discussed.
Purpose of the Study:
- To review the diverse applications of 18F-FDG PET/CT in breast cancer patient management.
- To highlight the utility of PET/CT in staging, treatment planning, recurrence detection, and response assessment.
Main Methods:
- Review of current literature and clinical applications of 18F-FDG PET/CT in breast cancer.
- Discussion of limitations, particularly in early-stage disease and axillary staging.
- Exploration of roles in locally advanced disease, recurrence, and treatment response evaluation.
Main Results:
- 18F-FDG PET/CT has limited value in early T1N0 tumors and cannot replace sentinel lymph node biopsy for axillary staging.
- In higher-risk and locally advanced breast cancer, PET/CT can identify nodal involvement and distant metastases, including osteomedullary infiltration.
- PET/CT is effective for whole-body staging, detecting recurrence, and assessing early response to chemotherapy.
Conclusions:
- 18F-FDG PET/CT is a crucial tool for specific clinical situations in breast cancer management, especially in higher-risk patients.
- Its ability to guide treatment planning, detect metastases, and monitor therapeutic efficacy makes it indispensable.
- Further research into new tracers complements the role of FDG-PET/CT.
